Market research
TAK Takeda Pharmaceutical Co Ltd ADR
NYSE USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 63B
- P/E ratio
- Not available
- Analyst target
- 22.7529
- Dividend yield
- 3.1%
- Beta
- 0.1
Profile
Instrument facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- Not available
- Market cap
- 63B
- P/E ratio
- Not available
- Analyst target
- 22.7529
- Dividend yield
- 3.1%
- Beta
- 0.1
About
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Research context
Takeda Pharmaceutical Co Ltd ADR appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TAK discussion.
5 years, 6 months ago
Takeda Pharmaceutical Company Limited is currently in a long term downtrend where the price is trading 5.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.0.
Takeda Pharmaceutical Company Limited's total revenue sank by 2.6% to $837B since the same quarter in the previous year.
Its net income has increased by 386.6% to $92B since the same quarter in the previous year.
Finally, its free cash flow grew by 168.9% to $174B since the same quarter in the previous year.
Based on the above factors, Takeda Pharmaceutical Company Limited gets an overall score of 3/5.